Spectral Genomics Forges License Agreement With Affymetrix
Spectral Genomics, Inc. of Houston, Texas announced today that it has entered a License Agreement that provides Spectral with a worldwide license to certain Affymetrix (NASDAQ:AFFX) patents to manufacture and sell spotted DNA arrays for use in the research market.
The license supports Spectral Genomics' Spectral Chip(TM) and Constitutional Chip(TM) as well as its Spectral Genomic Profiling(TM) service business. This license provides additional intellectual property enhancing Spectral's proprietary position in BAC clone whole genome arrays for research in cytogenetics and molecular biology.
Spectral Genomics' Chief Executive Officer, Edward M. Chait, Ph.D. said, "We are very pleased to be a licensee of Affymetrix and to acknowledge the contribution they have made to the science and development of the market for nucleic acid arrays while re-enforcing our own position as a leader in technology for the genome."
Spectral Genomics develops and manufactures BAC clone arrays with 3000- 6000 spots that cover the entire genome representing all the chromosomes at ten times higher resolution than with traditional cytogenetic techniques. These arrays are used in research in pre-natal and post-natal genetic defects and in cancer research. Spectral Genomics has headquarters in Houston, Texas and markets its products worldwide.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Viperidae
Shire to combine with Baxalta - Combination creates global biotechnology company
OMEICOS Secures Extension of Series B Financing Round
E._Thayer_Gaston
List_of_hummingbirds_in_taxonomic_order
Bismarck_brown_Y
Hypokalemic_periodic_paralysis

New strategy for COVID-19 prophylaxis - Researchers specifically stimulate the RNA receptor RIG-I, which improves protection against lethal SARS-CoV-2 infections
Carl Zeiss Licences Digital Pathology from Olympus
Hemlock_woolly_adelgid
British_Deaf_Association
